Sinoatrial Node Cell Purification via Anti-HCN4 Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating sinoatrial node (SAN) cells are limited by the lack of robust in vitro derivation methods and purification techniques, hindering the investigation of therapeutic effects on SAN function and drug discovery.
Innovation Solution
A method is developed to generate human pluripotent stem cell-derived SAN cells using a dual SHOX2:GFP; MYH6:mCherry knock-in reporter line, involving specific culture conditions and inhibitors to purify cells displaying molecular and electrophysiological characteristics of SAN cells, enabling their use for drug screening and toxicity evaluation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If in vivo direct conversion or NKX2.5 negative selection approach is used to obtain nodal like cells, then nodal like cells can be obtained, but purification method is lacking and cellular and molecular level characterization is limited
Solution Approach 1:
The patent introduces an intermediary purification step using anti-HCN4 antibodies to isolate nodal like cells from the heterogeneous cell population. This intermediary purification method enables precise cellular and molecular level characterization by separating target cells from non-target cells, resolving the contradiction between obtaining nodal like cells and achieving accurate characterization.
Solution Approach 2:
The patent employs fluorescently labeled anti-HCN4 antibodies that bind to HCN4 channels on nodal like cells, causing them to exhibit detectable fluorescent signals. This color/fluorescence change enables identification and isolation of pure nodal like cell populations, thereby achieving both purification and precise characterization simultaneously.
2Productivity
If robust in vitro derivation methods are developed, then cells with SAN characteristics can be generated, but current methods lack purification capability
Solution Approach 1:
The patent introduces antibody-based purification as an intermediary step between cell derivation and application. The anti-HCN4 antibodies specifically bind to HCN4 channels expressed on SAN cell surfaces, enabling reliable isolation of pure SAN cell populations from derived heterogeneous cultures, thus resolving the contradiction between productivity and reliability.
3Measurement precision
If HCN4 channel blockers are tested on nodal like cells, then effects on pacemaker activity can be investigated, but without purification the results may be confounded by other cell types
Solution Approach 1:
The patent uses anti-HCN4 antibodies as an intermediary tool to purify nodal like cells before conducting pharmacological experiments. This purification step ensures that observed effects of HCN4 channel blockers are specifically due to their action on nodal like cells rather than confounding effects from other cell types, thereby improving measurement precision while maintaining manageable experimental complexity.
Data Source
AI summary
Provided are methods for producing population of cells enriched for cells exhibiting sinoatrial node like characteristics. The cells can be produced from human pluripotent cells. Also provided are methods for using the SAN-like cells for identifying agents that can mitigate drug-induced cardiac toxicity. Also provided is a method for mitigating drug induced cardiotoxicity comprising administering to a subject an effective amount of physcion or a derivative thereof.